Petter Bjorquist, PhD Verigraft AB

Petter Bjorquist, PhD

Petter Bjorquist, PhD Verigraft AB

Petter holds a PhD in Biology/Biochemistry from Gothenburg University. He has 50 + publications in peer reviewed journals, several book chapters and patents.

Petter has spent ten years within AstraZeneca R&D in Cardiovascular Diseases, twelve years at Cellartis/Cellectis as VP Regenerative Medicine, where he was responsible for e.g. the major collaboration with Novo Nordisk on development of a human embryonic stem cell derived beta cell treatment for diabetes.

Also, he was responsible for development of human pluripotent stem cell derived cardiomyocytes and hepatocytes.

As of February 2014, CEO of VERIGRAFT AB, a pioneering company within tissue engineering and advanced regenerative medicine for use in treatment of cardiovascular and other diseases. Currently board member of a South Korean biotechnology company (GemVax group), and of publicly listed Swedish company Phase Holographic Imaging.